Kara Batte
YOU?
Author Swipe
Blockade of interleukin-6 (IL-6) signaling in dedifferentiated liposarcoma (DDLPS) decreases mouse double minute 2 (MDM2) oncogenicity via alternative splicing Open
Effective therapies for retroperitoneal (RP) dedifferentiated liposarcoma (DDLPS) remain unavailable. Loco-regional recurrence occurs in >80% of cases; 5-year disease-specific survival is only 20%. DDLPS is especially prevalent in the retr…
Blockade of interleukin-6 (IL-6) signaling in dedifferentiated liposarcoma (DDLPS) decreases mouse double minute 2 (MDM2) oncogenicity via alternative splicing Open
Effective therapies for retroperitoneal (RP) dedifferentiated liposarcoma (DDLPS) remain unavailable. Loco-regional recurrence occurs in >80% of cases; 5-year disease-specific survival is only 20%. DDLPS is especially prevalent in the retr…
Blockade of Interleukin-6 (IL-6) Signaling in Dedifferentiated Liposarcoma (DDLPS) Decreases Mouse Double Minute 2 (MDM2) Oncogenicity via Alternative Splicing Open
Effective therapies for retroperitoneal (RP) dedifferentiated liposarcoma (DDLPS) remain unavailable. Loco-regional recurrence occurs in >80% of cases; 5-year disease-specific survival is only 20%. DDLPS is especially prevalent in the retr…
View article: Data from Exosome-Derived miR-25-3p and miR-92a-3p Stimulate Liposarcoma Progression
Data from Exosome-Derived miR-25-3p and miR-92a-3p Stimulate Liposarcoma Progression Open
Despite the development of combined modality treatments against liposarcoma in recent years, a significant proportion of patients respond only modestly to such approaches, possibly contributing to local or distant recurrence. Early detecti…
View article: Supplementary Information from Exosome-Derived miR-25-3p and miR-92a-3p Stimulate Liposarcoma Progression
Supplementary Information from Exosome-Derived miR-25-3p and miR-92a-3p Stimulate Liposarcoma Progression Open
Supplementary Table S1. Detailed information about patients (A) and control group (B)used in the discovery set; Supplementary Table S2. Detailed information about patients (A) and control group (B) used in the validation set; Supplementary…
View article: Data from Exosome-Derived miR-25-3p and miR-92a-3p Stimulate Liposarcoma Progression
Data from Exosome-Derived miR-25-3p and miR-92a-3p Stimulate Liposarcoma Progression Open
Despite the development of combined modality treatments against liposarcoma in recent years, a significant proportion of patients respond only modestly to such approaches, possibly contributing to local or distant recurrence. Early detecti…
View article: Supplementary Information from Exosome-Derived miR-25-3p and miR-92a-3p Stimulate Liposarcoma Progression
Supplementary Information from Exosome-Derived miR-25-3p and miR-92a-3p Stimulate Liposarcoma Progression Open
Supplementary Table S1. Detailed information about patients (A) and control group (B)used in the discovery set; Supplementary Table S2. Detailed information about patients (A) and control group (B) used in the validation set; Supplementary…
Preclinical efficacy of the Wnt/β-catenin pathway inhibitor BC2059 for the treatment of desmoid tumors Open
Mutation in the CTNNB1 gene, leading to a deregulation of the WTN/β-catenin pathway, is a common feature of desmoid tumors (DTs). Many β-catenin inhibitors have recently been tested in clinical studies; however, BC2059 (also referred as Te…
β-catenin S45F mutation results in apoptotic resistance Open
Wnt/β-catenin signaling is one of the key cascades regulating embryogenesis and tissue homeostasis; it has also been intimately associated with carcinogenesis. This pathway is deregulated in several tumors, including colorectal cancer, bre…
Autophagy inhibition overcomes sorafenib resistance in S45F‐mutated desmoid tumors Open
Background Desmoid tumors (DTs) are rare and understudied fibroblastic lesions that are frequently recurrent and locally invasive. DT patients often experience chronic pain, organ dysfunction, decrease in quality of life, and even death. M…
Mocetinostat combined with gemcitabine for the treatment of leiomyosarcoma: Preclinical correlates Open
Leiomyosarcoma (LMS) is a malignant soft tissue sarcoma (STS) with a dismal prognosis following metastatic disease. Chemotherapeutic intervention has demonstrated to have modest clinical efficacy with no curative potential in LMS patients.…
Exosome-Derived miR-25-3p and miR-92a-3p Stimulate Liposarcoma Progression Open
Despite the development of combined modality treatments against liposarcoma in recent years, a significant proportion of patients respond only modestly to such approaches, possibly contributing to local or distant recurrence. Early detecti…
Verticillin A Inhibits Leiomyosarcoma and Malignant Peripheral Nerve Sheath Tumor Growth via Induction of Apoptosis Open
Advancement in the treatment of karyotypically complex STS is confounded by the high level of genetic abnormalities found in these diseases. Consequently, the identification and investigation of novel therapies is greatly needed. Our data …